Home
About Us
Team
Services
News
Partners
Advisory Board
Contact
News
Oxeia Announces Positive Interim Results of Phase 2 Trial for OXE103 for the Treatment of Concussions
Genetic Engineering & Biotechnology News – Bitter Taste Receptors Represent a Therapeutic Sweet Spot
Aardvark Therapeutics, Inc., Announces the Initiation of Enrollment for Three Phase 2 Clinical Trials Of Oral ARD-101
Oxeia Biopharmaceuticals Announces New Board and Management Team Members and Relocates Corporate Headquarters To Boston
Swiss Gondola Medical Technologies Announces Collaboration with New York’s Mount Sinai Health System to Study Innovative Treatment for Neurological Disorders Such as Parkinson’s Disease
Back To Top